Gamida Cell is a cell therapy company working to turn cells into therapeutics. Co. applies a proprietary expansion platform utilizing the properties of nicotinamide to allogeneic cell sources including umbilical cord blood-derived cells and natural killer (NK) cells to create cell therapy candidates. Co.'s primary product candidate, omidubicel, is a cell therapy for allogeneic hematopoietic stem cell transplant. Co.'s clinical stage NK cell therapy candidate, GDA-201, is in the Phase 1/2 clinical trial of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas. We show 12 historical shares outstanding datapoints in our GMDA shares outstanding history coverage, used to compute GMDA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GMDA market cap history over the course of time is important for investors
interested in comparing GMDA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GMDA versus a peer is one thing; comparing
GMDA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GMDA can fluctuate over the course of history.
With this page we aim to empower investors researching GMDA by allowing them to research the GMDA market cap history. |
Free GMDA Email Alerts:
Video: The Importance of Market Cap
